A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Cofetuzumab pelidotin (Primary) ; Avelumab; Fluconazole
- Indications Advanced breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 12 Oct 2019 Planned End Date changed from 20 Sep 2019 to 4 Nov 2019.
- 12 Oct 2019 Planned primary completion date changed from 20 Sep 2019 to 4 Nov 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History